Prediction and Detection of Occult Atrial Fibrillation in Patients After Acute Cryptogenic Stroke and TIA (PROACTIA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02725944|
Recruitment Status : Completed
First Posted : April 1, 2016
Last Update Posted : September 10, 2018
|Condition or disease||Intervention/treatment|
|Cerebrovascular Stroke Atrial Fibrillation||Device: Implantation of ICRM|
It will be enrolled 250 participants of both sexes within two weeks after diagnosed cryptogenic stroke and/or TIA at Akershus University Hospital, Oslo area, Norway.
Evaluation of participants' comorbidity with CHADS2-VASc score, ECG, Holter ECG, echocardiography, detection of biochemical cardiac markers and screening for obstructive sleep apnea syndrome will be performed. All participants will be monitored with a continuous cardiac rhythm during one year by implantation of implantable cardiac rhythm monitors (ICRM). All patients without high bleeding risk will get prescribed oral anticoagulants (OAC) after detection of PAF.
A biobank will be established in order to store the sampled biological material.
|Study Type :||Observational|
|Actual Enrollment :||251 participants|
|Official Title:||Prediction and Detection of Occult Atrial Fibrillation in Patients After Acute Cryptogenic Stroke and Transient Ischemic Attack|
|Actual Study Start Date :||May 15, 2016|
|Actual Primary Completion Date :||June 18, 2018|
|Actual Study Completion Date :||June 18, 2018|
Patients with cryptogenic stroke and TIA
Implantation of ICRM in all participants.
Device: Implantation of ICRM
All patients will be implanted with ICRM in order to detect an occult PAF.
- Detection of paroxysmal atrial fibrillation [ Time Frame: One year ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02725944
|Oslo, Akershus, Norway, 1478|